We previously revealed a role for EZH2 in inducing pro-inflammatory epigenetic changes in lupus CD4+ T cells. In this study, we sought to determine if inhibiting EZH2 ameliorates lupus-like disease in MRL/lpr mice.
Introduction
Systemic Lupus Erythematosus (SLE or lupus) is a chronic relapsing autoimmune disease that involves multiple organ systems. Lupus is characterized by the production of autoantibodies directed against nuclear antigens, and a dysregulated immune response. The etiology of lupus remains unknown, however, both genetic and epigenetic mechanisms have been shown to contribute to disease pathogenesis (1, 2) .
DNA methylation plays a critical role in the pathogenesis of lupus (3) . Abnormal DNA methylation patterns have been described in multiple immune cell types isolated from lupus patients, and a role for genetic-epigenetic interaction in the pathogenesis of lupus has been suggested (4) . Further, abnormal DNA methylation patterns in lupus have been shown to contribute to clinical heterogeneity, disease variability between ethnicities, and lupus flare and remission (4) .
We have recently demonstrated that increased disease activity in lupus patients is characterized by an early epigenetic shift in naïve CD4+ T cells the precedes CD4+ T cell differentiation and effector T cell transcriptional activity (5) . We provided evidence that this epigenetic shift is likely induced by EZH2 overexpression as a result of downregulation of miR-101 and miR-26a, and demonstrated that EZH2 overexpression mediates increased T cell adhesion in lupus due to EZH2-induced demethylation and transcriptional de-repression of the adhesion molecule JAM-A (5, 6) .
EZH2 overexpression has been linked to increased invasiveness in a number of malignancies, and EZH2 inhibitors are currently being evaluated in clinical trials for cancer therapy (7) . Our data indicate that inhibiting EZH2 might be of therapeutic potential in lupus, suggesting the possibility of pharmacologic repurposing of EHZ2 4 inhibitors as a therapeutic option for lupus. In this study, we first examined EZH2 expression patterns in other immune cell types isolated from the peripheral blood of lupus patients, and then tested the effects of using an EZH2 inhibitor in the lupus-prone MRL/lpr mouse model, utilizing both preventative and therapeutic approaches. Our data provide robust pre-clinical evidence supporting the potential use of EZH2 inhibitors in lupus, paving the way for repurposing EZH2 inhibitors in lupus clinical trials.
Materials and Methods

EZH2 expression in B cells, monocytes, and neutrophils in lupus patients.
We recruited a total of six lupus patients (mean ± SEM age: 46.2 ± 5.4; age range: 32 to 61 years) and six healthy controls (mean ± SEM age: 44.5 ± 5.8; age range: 30 to 63 years). All lupus patients fulfilled the American College of Rheumatology classification criteria for SLE (8) . The mean SLEDAI score for lupus patients was 2 with a median of 1 (range: 0 to 6). Lupus patients on cyclophosphamide or methotrexate were excluded from participating in the study. All participants signed informed consent approved by the institutional review board of the University of Michigan. Peripheral whole blood was collected from each study subject, and erythrocytes in blood samples were lysed with RBC Lysis Buffer (eBioscience). Lysed whole blood cells were incubated with Human Seroblock (BIO-RAD) in cell staining buffer (BioLegend) to block unspecific Fc receptor binding of Ig, and extracellularly stained with the following fluorochrome-conjugated antibodies: APC/Cy7 anti-CD14 (clone: 63D3, BioLegend), PE Mouse Anti-Human CD16b (clone: CLB-gran11.5 (RUO), BD Biosciences), APC anti-CD19 (clone: HIB19, BioLegend). Afterward, cells were fixed with Fixation Buffer (BioLegend), permeabilized with Intracellular Staining Permeabilization Wash Buffer (BioLegend), and subsequently stained with FITC anti-EZH2 (clone: REA907, Miltenyi Biotec) or with corresponding isotype control, REA Control (I) antibody (clone: REA293, Miltenyi Biotec). Stained cells were then analyzed by flow cytometry using an iCyt Synergy SY3200 Cell Sorter (Sony Biotechnology Inc.) and by FlowJo software v10.0.7 (Treestar). An example of the gating strategy to determine B cells, monocytes, and neutrophils is shown in Supplementary Figure 1 , based on FSC versus SSC and positive expression of their 6 respective markers. The expression of EZH2 is measured by median fluorescence intensity (MFI) of EZH2 antibody minus MFI of its isotype control.
GEO data analysis. Analysis of EZH2 mRNA expression levels between lupus patients and healthy controls (in whole blood cells, CD4+ T cells, and CD19+ B cells) was performed using datasets downloaded from Gene Expression Omnibus (GEO) (accession numbers GSE72509 and GDS4185). These datasets have been described in detail previously (9, 10). Urine was collected every two weeks beginning two weeks prior to Day 0 of the study. Urine albumin and creatinine concentrations were measured using enzymelinked immunosorbent assay (ELISA) kits from Alpha Diagnostic and R& D system, respectively, and used to calculate the urine albumin-to-creatinine ratio (UACR). P-values of less than 0.05 were considered statistically significant. Data are presented as mean ± SEM.
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Results
EZH2 expression in lupus.
We previously showed that EZH2 is upregulated in lupus CD4+ T cells, and that T cell overexpression of EZH2 plays an important role in lupus (5, 6) . To examine if other immune cell types also overexpress EZH2 in lupus, we determined EZH2 expression using flow cytometry in B cells, monocytes, and neutrophils isolated from peripheral blood from lupus patients compared to normal healthy controls. EZH2 expression, as determined by median fluorescence intensity (MFI), was significantly elevated in B cells, monocytes, and neutrophils of lupus patients compared to matched controls (p<0.05; Figures 1A, 1B, and 1C) . Using previously published gene expression profiles available in Gene Expression Omnibus (GEO), we analyzed EZH2 mRNA levels in whole blood (GEO accession GSE72509) and freshly isolated lymphocyte subsets (GEO Accession GDS4185) of lupus patients and healthy controls. EZH2 mRNA levels in whole blood of lupus patients were significantly higher than healthy controls (p<0.01; Figure 1D) . Similarly, EZH2 expression was significantly elevated in the freshly isolated B cells and CD4+ T cells of lupus patients when compared to controls (p<0.05; Figures 1E and1F) .
Effect of EZH2 inhibition on mortality and autoantibody production in MRL/lpr
mice. To examine if inhibition of EZH2 is beneficial in lupus-like disease, an EZH2 inhibitor, DZNep, was administered to MRL/lpr mice (Figure 2A and 2B) . As shown in There was no difference in the total number of B cells (CD19+TCRβ-cells) between any groups (Figure 5E) . We observed, however that the B cell percentage of total splenocytes (CD19+TCRβ-cells of total splenocytes) was significantly greater in both the DZNep/DZNep and Vehicle/DZNep groups when compared to controls (p≤0.0001; Figure 5F ).
Cytokine analysis.
To further characterize the effect of EZH2 inhibition in MRL/lpr mice, we analyzed the differential expression of plasma cytokine levels at day 98.
Cytokine levels were undetectable for IL-3, IL-1b, IL-9, IL-13, IL-6, IL-4, G-CSF, GM-CSF, and MIP-1a. No significant differences were observed between DZNep treatment groups and vehicle controls for IL-2, IL-5, IL1a, IL-17a, and Exotaxin/CCL11 (data not 14 shown). However, there was a significant reduction in plasma levels of TNF, IFN-γ, CCL2, RANTES/CCL5, IL-10, KC/CXCL1, IL-12, IL-12p40 and MIP-1β/CCL4 in both the DZNep/DZNep-treated and Vehicle/DZNep-treated groups when compared to the Vehicle control group (Figure 6) . 15 
Discussion
Our previous work suggested that EZH2 plays an important role in lupus (5, 6) .
We reported that naïve CD4+ T cells from lupus patients had higher expression levels of EZH2 than healthy controls, and this upregulation is critical for T cell adhesion, as inhibition of EZH2 by DZNep can normalize the ability of lupus CD4+ T cells to adhere to endothelial cells (6) . In this study we further examined the expression of EZH2 in other cell types and showed that EZH2 was significantly upregulated in B cells, monocytes, and neutrophils in lupus patients. These data prompted us to investigate whether inhibition of EZH2 would be beneficial for lupus. Indeed, in MRL/lpr mice, DZNep treatment, either dosing following a preventative or a therapeutic fashion, improved survival and reduced autoantibody production. In addition, the therapeutic effects of DZNep appear rapidly, as lowering anti-dsDNA antibody levels and UACR were evident 14 days following the first dose of DZNep.
The improvement in survival observed in DZNep-treated mice is likely in part due to a reduction in renal involvement. DZNep treatments appeared to prevent the progression of renal damage, as evidenced by relatively steady UACR in DZNeptreated mice. Renal damage was also assessed at the end of the study through histopathological examination. We observed a significant reduction in glomerulonephritis and crescent formation in both DZNep treatment groups, and a The MRL/lpr mouse model is a lymphoproliferative model characterized by T cell and B cell dysregulation (11) . The infiltration of DN T cells, in addition to an overall hyperproliferation of T cell populations contribute significantly to the observed splenomegaly and lymphadenopathy in MRL/lpr mice (11, 12) . We observed a significant reduction in spleen and lymph node weights in both groups of mice treated with DZNep. A significant reduction in the total number of splenocytes in DZNep-treated groups was also observed, suggesting a reduction in lymphoproliferation. While DZNep treatment in both groups reduced the total number of T cells, CD4+ T cells, and CD8+ T
cells, the reduction in CD4-CD8-T cells (DN T cells) is of particular interest. DN T cells represent a pathogenic T cell subset in lupus likely derived from CD8+ T cells (13). DN
T cells contribute to the production of autoantibodies, produce significant amounts of inflammatory cytokines including IL-17 and IFN-γ, and contribute to renal damage as they accumulate in the kidneys of lupus patients (13) (14) (15) (16) . Inhibition of EZH2 with DZNep significantly reduced the total number of pathogenic DN T cells in MRL/lpr mice. Indeed, the significant reduction in DN T cell numbers observed with DZNep caused significant elevation in the percentages of the single positive T cells (CD4+ and CD8+ T cells). We speculate that the reduction of pathogenic DN T cells in the DZNep-treated groups likely contributed to the observed reduction in renal damage and levels of circulating autoantibodies.
Cytokine and chemokine production are important in lupus pathogenesis and tissue damage in lupus patients. We observed reduced concentrations of TNF, IFN-γ, CCL2, RANTES/CCL5, IL-10, IL-12, IL-12p40, and MIP-1β/CCL4 in the plasma of the DZNep-treated groups compared to controls. All of these cytokines and chemokines have been reported to be elevated in lupus patients (17) (18) (19) (20) (21) . Chemokines such as RANTES/CCL5, MCP-1/CCL2, and MIP-1β/CCL4 contribute to lupus pathogenesis by recruiting leukocytes and other effector cells to inflamed tissues, causing damage (17) (18) (19) . IL-10 and TNF have been reported to be upregulated and correlated with disease activity in lupus patients experiencing renal involvement (17, 20) . IFN-γ has been shown to contribute to the development of lupus through promotion of autophagy in lupus T cells, and potentially the persistence of pathogenic T cell subsets (20) . Dysregulation of IL-12 has been reported in patients with lupus (22) , and a recent clinical trial adding ustekinumab, which targets IL-12p40, to standard-of-care in lupus patients in a phase II trial showed promising results (23) .
We have previously demonstrated that EZH2 might mediate a pathogenic effect in lupus though altering T cell DNA methylation patterns and upregulation of the adhesion molecule JAM-A in CD4+ T cells (5, 6) . As the Notch signaling pathway regulates effector T cell survival and function including cytokine production (24) (25) (26) , we speculate that another potential mechanism of action for EZH2 in lupus might involve the Notch signaling pathway. EZH2 has been shown to inhibit T cell Notch repressors, promoting Notch activation and thus effector T cell polyfunctionality and survival (27) .
Notch pathway is also critical in B cells and monocytes (28) (29) (30) (31) (32) , which are also characterized by EZH2 overexpression in lupus in our study.
In summary, we demonstrate that EZH2 in overexpressed in multiple immune cell types in lupus patients. Inhibiting EZH2 is associated with abrogation of lupus-like disease in 
